| 王 剑,车玲艳,谢华宁,张荣怀,刘富强.银杏蜜环口服溶液联合尼可地尔对冠心病患者血清HsCRP、HCY、IMA、LP-PLA2水平的影响[J].现代生物医学进展英文版,2019,19(23):4545-4548. |
| 银杏蜜环口服溶液联合尼可地尔对冠心病患者血清HsCRP、HCY、IMA、LP-PLA2水平的影响 |
| Effect of Ginkgo Leaf Extract and Armillariella Mellea Powders Oral Solution Combined with Nicorandil on the Serum Levels of HsCRP, HCY, IMA and LP-PLA2 in Patients with Coronary Heart Disease |
| Received:March 06, 2019 Revised:March 30, 2019 |
| DOI：10.13241/j.cnki.pmb.2019.23.034 |
| 中文关键词: 银杏蜜环口服溶液 尼可地尔 冠心病 |
| 英文关键词: Ginkgo Leaf Extract and Armillariella Mellea Powders Oral Solution Nicorandil Coronary heart disease |
| 基金项目:陕西省自然科学基础研究计划-青年人才项目（2014JQ2-8050） |
| Author Name | Affiliation | E-mail | | WANG Jian | General medicine Department, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, Shaanxi, 710003, China | ww51922390@163.com | | CHE Ling-yan | Emergency Department, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, Shaanxi, 710003, China | | | XIE Hua-ning | Heart Disease Department, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, Shaanxi, 710003, China | | | ZHANG Rong-huai | Cardiology Department, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710068, China | | | LIU Fu-qiang | Cardiology Department, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710068, China | |
|
| Hits: 909 |
| Download times: 647 |
| 中文摘要: |
| 摘要 目的：研究银杏蜜环口服溶液联合尼可地尔对冠心病患者血清超敏C反应蛋白(High-sensitivity C-reactive protein，HsCRP)、同型半胱氨酸(Homocysteine，HCY)、缺血修饰白蛋白(Ischemia Modified Albumin，IMA)和脂蛋白相关磷脂酶A2(Lipoprotein-related phospholipase A2，Lp-PLA2)水平的影响。方法：选择2016年11月～2018年11月在我院全科医学科、急诊科收治的80例冠心病患者，根据就诊顺序，用抽签法随机分为两组，每组40例患者。对照组口服尼可地尔治疗，观察组采取银杏蜜环口服溶液联合尼可地尔治疗，两组均持续治疗2周。比较两组治疗前后的血清HsCRP、HCY、IMA、LP-PLA2水平，左室舒张末径(left ventricular end-diastolic diameter，LVEDD)、心输出量(cardiac output，CO)和左室射血分数(left ventricular ejection fraction，LVEF)等心功能指标的变化。结果：治疗后，观察组的总有效率为92.50%(37/40)，明显高于对照组[75.00%(30/40)](P<0.05)；两组治疗后的血清HsCRP、HCY、IMA、LP-PLA2水平均较治疗前明显降低(P<0.05)，且观察组以上指标均明显低于对照组(P<0.05)；两组治疗后的LVEDD均较治疗前明显降低，而CO和LVEF均较治疗前明显升高(P均<0.05)，且观察组治疗后的LVEDD与对照组相比明显降低，而CO和LVEF显著升高(P<0.05)。结论：银杏蜜环口服溶液联合尼可地尔治疗冠心病的疗效明显优于单独口服尼可地尔治疗，其机制可能与降低血清HsCRP、HCY、IMA、LP-PLA2水平相关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Ginkgo Leaf Extract and Armillariella Mellea Powders Oral Solution combined with nicorandil on the serum levels of high-sensitivity C-reactive protein(HsCRP), homocysteine(HCY), ischemia-modified albumin (IMA) and lipoprotein- related phospholipase A2 (Lp-PLA2) levels in patients with coronary heart disease. Methods: Eighty patients with coronary heart disease admitted to our department of general medicine and emergency department from November 2016 to November 2018 were randomly divided into two groups according to the order of treatment, with 40 patients in each group. The control group was treated with nicorandil, and the observation group was treated with ginkgo melamine oral solution combined with nicorandil. Both groups continued treatment for 2 weeks. Serum HsCRP, HCY, IMA, LP-PLA2 levels, left ventricular end-diastolic diameter(LVEDD), cardiac output(CO), and left ventricular ejection fraction were compared between the two groups. Left ventricular ejection fraction (LVEF) changes in cardiac function indicators. Results: After treatment, the total effective rate of observation group was 92.50% (37/40), which was significantly higher than that of the control group [75.00% (30/40)](P<0.05). The levels of serum HsCRP, HCY, IMA and LP-PLA2 in both groups were significantly lower than those before treatment(P<0.05), and the above indicators in the observation group were significantly lower than the control group(P<0.05). The LVEDD of the two groups was significantly lower than that before treatment, and CO and LVEF were significantly higher than those before treatment(P<0.05), and the LVEDD after treatment in the observation group was significantly lower than that of the control group, while CO and LVEF were significantly increased (P<0.05). Conclusion: The efficacy of ginkgo biloba oral solution combined with nicorandil was significantly better than that of nicorandil alone in the treatment of coronary heart disease. The mechanism may be related to the reduction of serum HsCRP, HCY, IMA and LP-PLA2 levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
